Recombinant Human Tyrosine-Protein Phosphatase Non-Receptor Type 6 (PTPN6) Protein (His-SUMO)

Name: Recombinant Human Tyrosine-Protein Phosphatase Non-Receptor Type 6 (PTPN6) Protein (His-SUMO)
Brand: Beta LifeScience
SKU: BLC-04342P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Tyrosine-Protein Phosphatase Non-Receptor Type 6 (PTPN6) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P29350
Target Symbol	PTPN6
Synonyms	70Z-SHP; EC 3.1.3.48; HCP; HCPH; Hematopoietic cell phosphatase ; Hematopoietic cell protein tyrosine phosphatase; Hematopoietic cell protein-tyrosine phosphatase; HPTP1C; Protein tyrosine phosphatase 1C; Protein tyrosine phosphatase non receptor type 6; Protein tyrosine phosphatase SHP1; Protein-tyrosine phosphatase 1C; protein-tyrosine phosphatase SHP 1; Protein-tyrosine phosphatase SHP-1; PTN6_HUMAN; PTP 1C; PTP-1C; PTP1C; Ptpn6; SH PTP 1; SH PTP1; SH-PTP1; SHP 1; SHP 1L; SHP1; SHP1L; tyrosine protein phosphatase non receptor type 6; Tyrosine-protein phosphatase non-receptor type 6
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His-SUMO
Target Protein Sequence	MLSRGWFHRDLSGLDAETLLKGRGVHGSFLARPSRKNQGDFSLSVRVGDQVTHIRIQNSGDFYDLYGGEKFATLTELVEYYTQQQGVLQDRDGTIIHLKYPLNCSDPTSERWYHGHMSGGQAETLLQAKGEPWTFLVRESLSQPGDFVLSVLSDQPKAGPGSPLRVTHIKVMCEGGRYTVGGLETFDSLTDLVEHFKKTGIEEASGAFVYLRQPYYATRVNAADIENRVLELNKKQESEDTAKAGFWEEFESLQKQEVKNLHQRLEGQRPENKGKNRYKNILPFDHSRVILQGRDSNIPGSDYINANYIKNQLLGPDENAKTYIASQGCLEATVNDFWQMAWQENSRVIVMTTREVEKGRNKCVPYWPEVGMQRAYGPYSVTNCGEHDTTEYKLRTLQVSPLDNGDLIREIWHYQYLSWPDHGVPSEPGGVLSFLDQINQRQESLPHAGPIIVHCSAGIGRTGTIIVIDMLMENISTKGLDCDIDIQKTIQMVRAQRSGMVQTEAQYKFIYVAIAQFIETTKKKLEVLQSQKGQESEYGNITYPPAMKNAHAKASRTSSKHKEDVYENLHTKNKREEKVKKQRSADKEKSKGSLKRK
Expression Range	1-597aa
Protein Length	Full Length of Isoform 2
Mol. Weight	79.1kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Modulates signaling by tyrosine phosphorylated cell surface receptors such as KIT and the EGF receptor/EGFR. The SH2 regions may interact with other cellular components to modulate its own phosphatase activity against interacting substrates. Together with MTUS1, induces UBE2V2 expression upon angiotensin II stimulation. Plays a key role in hematopoiesis.
Subcellular Location	Cytoplasm. Nucleus.
Protein Families	Protein-tyrosine phosphatase family, Non-receptor class 2 subfamily
Database References	HGNC: 9658 OMIM: 176883 KEGG: hsa:5777 STRING: 9606.ENSP00000391592 UniGene: PMID: 28533521 actomyosin retrograde flow controls the immune response of primary human Natural killer cells through a novel interaction between beta-actin and the SH2-domain-containing protein tyrosine phosphatase-1 (SHP-1), converting its conformation state, and thereby regulating Natural killer cell cytotoxicity. PMID: 29449322 Biophysical assay for tethered signaling reactions reveals tether-controlled activity for the phosphatase SHP-1. PMID: 28378014 This study demonstrates that VB inhibits glioblastoma cell proliferation, migration, and invasion while promoting apoptosis via SHP-1 activation and inhibition of STAT3 phosphorylation. PMID: 29961065 M. tuberculosis-initiated human mannose receptor signaling regulates macrophage recognition and vesicle trafficking by gamma Fc receptors, Grb2, and SHP-1. PMID: 28978467 Data suggest that SHP-1/p-STAT3/VEGF-A axis is a potential therapeutic target for metastatic triple-negative breast cancer (TNBC). PMID: 27364975 these data highlight a signaling pathway in which SHP-1 acts through CrkII to reshape the pattern of Rap1 activation in the immunological synapse. PMID: 28790195 observations suggest that Chikungunya virus (CHIKV) has the ability to induce host PTPN6 expression, and induction of PTPN6 may favour the attenuation of the pro-inflammatory immune response of the host, which is otherwise detrimental for the survival of CHIKV and establishment of an infection PMID: 29058147 The results reveal that SHP1 is the long-sought phosphatase that can antagonize Helicobacter pylori CagA. Augmented Helicobacter pylori CagA activity, via SHP1 inhibition, might also contribute to the development of Epstein-Barr virus-positive gastric cancer. PMID: 27572445 Analyzed gene expression profiles of monocytes from symptomatic congestive heart failure patients; there is a down-regulation of the phosphatase SHP-1 which induces a significant activation of TAK-1/IKK/NF-kB signaling. PMID: 27814644 crocin induced the expression of SHP-1, a tyrosine protein phosphatase, and pervanadate treatment reversed the crocin-induced downregulation of STAT3, suggesting the involvement of a protein tyrosine phosphatase. PMID: 28295507 this review focalizes upon the implication of SHP-1 in the pathogenesis of autoimmune disorders, and addresses developing therapeutic strategies targeting SHP-1 PMID: 27216862 we demonstrated that SHP-1 dephosphorylates PKM2Y105 to inhibit the Warburg effect and nucleus-dependent cell proliferation, and the dephosphorylation of PKM2Y105 by SHP-1 determines the efficacy of targeted drugs for hepatocellular carcinoma treatment PMID: 26959741 These findings have provided first lines of evidences that PDZK1 expression is negatively correlated with SHP-1 activation and poor clinical outcomes in clear cell renal cell carcinoma (ccRCC) . PDZK1 was identified as a novel tumor suppressor in ccRCC by negating SHP-1 activity PMID: 28692056 luteolin inhibited STAT3 activation through disrupting the binding of HSP-90 to STAT3, which promoted its interaction to SHP-1. PMID: 28182003 These findings show a novel role for Shp-1 in the regulation of IEC growth and secretory lineage allocation, possibly via modulation of PI3K/Akt-dependent signaling pathways. PMID: 28465325 the role of Shp1 in myeloid cells and how its dysregulation affects immune function, which can impact human disease. PMID: 28606940 PTPN6 is associated with progression of chronic myeloid leukaemia. Low expression level of PTPN6 was associated with DNA methylation and regulated by histone acetylation PMID: 28480959 The Shp1 functions as a positive regulator and acts in a novel mechanism through promoting EGFR protein expression in human epithelial cells. PMID: 28416389 SHP1 DNA methylation in in patients with B cell non-Hodgkin lymphoma PMID: 28210822 these results indicate that DNMT1 mediates aberrant methylation and silencing of SHP-1 gene in chronic myelogenous leukemia cells PMID: 28376405 Results provide evidence that repression of SHP-1, SHP-2 and SOCS-1 gene expression in patient plasma cells supports the constitutive activation of the JAK/STAT3 pathway and probably leads to higher degrees of bone marrow invasion. PMID: 28369102 we found that THEMIS directly regulated the catalytic activity of the tyrosine phosphatase SHP-1. PMID: 28250424 Hyperglycemia induces SHP-1 promoter epigenetic modifications, causing its persistent expression and activity and leading to insulin resistance, podocyte dysfunction, and DN. PMID: 27585521 Low SHP1 expression is associated with primary central nervous system lymphoma. PMID: 27959415 study evaluated SHP1-P2 methylation levels in the lymph nodes of colorectal cancer (CRC) patients; hypothesized that SHP1-P2 methylation levels would be higher in metastatic lymph nodes PMID: 27644671 Overexpression of SHP1 downregulates the JAK2/STAT3 pathway to modulate various target genes and inhibit cell proliferation, migration, and invasion in gastric cancer cells. PMID: 26508024 This study also found no correlation of SHP-1 expression at diagnosis with response to treatment, although a trend for lower SHP-1 expression was noted in the very small non-responders' group of the 3-month therapeutic milestone. PMID: 26373709 SYK, LYN and PTPN6 were markedly elevated in atherosclerotic plaques of carotid atherosclerosis patients. PMID: 26742467 cAMP signalling of Bordetella adenylate cyclase toxin through the SHP-1 phosphatase activates the BimEL-Bax pro-apoptotic cascade in phagocytes. PMID: 26334669 Quinalizarin enhances radiosensitivity of nasopharyngeal carcinoma cells partially by suppressing SHP-1 expression PMID: 26781335 N225K and A550V PTPN6 mutations cause loss-of-function leading to JAK3 mediated deregulation of STAT3 pathway and uncover a mechanism that tumor cells can use to control PTPN6 substrate specificity. PMID: 26565811 In addition to their role in NK cell activation by hematopoietic cells, the SLAM-SAP-SHP1 pathways influence responsiveness toward nonhematopoietic targets by a process akin to NK cell 'education'. PMID: 26878112 A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo which reduces tumor size and prolonged survival time. PMID: 26679051 SHP-1 has a critical role in radioresistance, cell cycle progression, and senescence of nasopharyngeal carcinoma cells PMID: 26215037 Data demonstrate for the first time that SHP1 methylation has high specificity for diagnosis of endometrial carcinoma, while CDH13 promoter methylation plays a role in the earlier stage. PMID: 26597461 MiR-378g enhanced radiosensitivity partially by targeting SHP-1 in NPC cells. PMID: 26473472 Soluble egg antigens glycans are essential for induction of enhanced SOCS1 and SHP1 levels in dendritic cells via the mannose receptor. PMID: 25897665 miR-4649-3p is downregulated in nasopharyngeal carcinoma cell lines accompanied with SHP-1 upregulation. PMID: 26081980 Results show that dissociation of SHP-1 from spinophilin is followed by an increase in the binding of spinophilin to PP1. PMID: 25785436 Data show that SHP-1 promotes HIF-1alpha degradation under hypoxic conditions leading to a reduction in VEGF synthesis and secretion and impairing epithelial cells proliferation. PMID: 25799543 Phosphorylation of ATR and CHK1 did not show significant differences in the three cell groups. Overexpression of SHP-1 in the CNE-2 cells led to radioresistance and the radioresistance was related to enhanced DNA DSB repair. PMID: 25962492 SHP-1 is a potent suppressor of epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. PMID: 25619838 Inactivation of SHP1 is associated with myeloproliferative neoplasm. PMID: 25824741 Data suggest that protein tyrosine phosphatase non-receptor type 6 (SHP-1) may interact with EGF receptor (EGFR) to inhibit proliferation. PMID: 22797910 SHP-1 expression ws lower in PBMCs from unmedicated schizophrenics. The promoter region was hypermethylated. Silencing SHP-1 induced IKK/NF-kB and pro-inflammatory cytokines. SHP-1 expression may explain 30% of the clinical negative symptom variance. PMID: 24793756 SHP-1(I) presented concordance between unmethylated promoter region and tumor for breast or prostate. PMID: 25635370 A high level of SHP1P2 methylation of hilar lymph nodes from stage I NSCLC patients is associated with early relapse of disease. PMID: 23824557 transcription factor RFX-1 regulates SC-2001-mediated SHP-1 Phosphatase transcription in hepatocellular carcinoma cells. PMID: 24952874 decreased expression levels of SHP-1 caused by aberrant promoter hypermethylation may play a key role in the progression of CML by dysregulating BCR-ABL1, AKT, MAPK, MYC and JAK2/STAT5 signaling. PMID: 24647617

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

📧 inquiry@betalifesci.com 📞 +1(201) 888-7983

Contact Us Now for Inquiries, Orders, and Questions

Recombinant Human Tyrosine-Protein Phosphatase Non-Receptor Type 6 (PTPN6) Protein (His-SUMO)

Recombinant Human Tyrosine-Protein Phosphatase Non-Receptor Type 6 (PTPN6) Protein (His-SUMO)

Product Overview

Target Details

FAQs